ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $153,369 | -16.5% | 1,637,848 | -20.4% | 0.02% | -15.4% |
Q2 2023 | $183,602 | -49.2% | 2,057,164 | -39.0% | 0.03% | -51.9% |
Q1 2023 | $361,326 | -20.3% | 3,369,943 | -9.2% | 0.05% | -26.0% |
Q4 2022 | $453,083 | -99.9% | 3,709,841 | -4.3% | 0.07% | +10.6% |
Q3 2022 | $400,119,000 | -16.7% | 3,874,863 | -25.0% | 0.07% | +8.2% |
Q2 2022 | $480,173,000 | -16.0% | 5,165,375 | +6.1% | 0.06% | +5.2% |
Q1 2022 | $571,561,000 | -10.8% | 4,870,151 | +2.3% | 0.06% | 0.0% |
Q4 2021 | $640,523,000 | -16.9% | 4,761,193 | -1.5% | 0.06% | -20.5% |
Q3 2021 | $770,764,000 | +15.8% | 4,835,714 | -4.5% | 0.07% | +17.7% |
Q2 2021 | $665,808,000 | +1.8% | 5,061,254 | -0.2% | 0.06% | -4.6% |
Q1 2021 | $653,852,000 | -40.8% | 5,073,336 | -23.4% | 0.06% | -42.5% |
Q4 2020 | $1,103,924,000 | +5.5% | 6,619,042 | -2.3% | 0.11% | -6.6% |
Q3 2020 | $1,045,925,000 | +0.1% | 6,777,635 | -4.1% | 0.12% | -7.6% |
Q2 2020 | $1,044,822,000 | +29.0% | 7,064,384 | -1.8% | 0.13% | +2.3% |
Q1 2020 | $809,984,000 | -25.0% | 7,192,829 | -7.3% | 0.13% | -8.6% |
Q4 2019 | $1,079,751,000 | +44.2% | 7,761,296 | -0.2% | 0.14% | +32.1% |
Q3 2019 | $748,887,000 | -9.4% | 7,774,992 | +8.3% | 0.11% | -8.6% |
Q2 2019 | $826,551,000 | +50.4% | 7,178,036 | +53.7% | 0.12% | +43.2% |
Q1 2019 | $549,542,000 | +113.4% | 4,669,002 | +13.6% | 0.08% | +84.1% |
Q4 2018 | $257,547,000 | +7.5% | 4,110,892 | +21.6% | 0.04% | +25.7% |
Q3 2018 | $239,634,000 | +16.2% | 3,381,796 | +9.1% | 0.04% | +9.4% |
Q2 2018 | $206,152,000 | +11.9% | 3,099,099 | +10.0% | 0.03% | +10.3% |
Q1 2018 | $184,287,000 | +913.3% | 2,817,838 | +520.7% | 0.03% | +866.7% |
Q4 2017 | $18,186,000 | – | 453,970 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |